|
RENALDO
Renin-Aldosterone
Ongoing trial
 |
Author(s) |
Parthasarathy HK, Alhashmi K, McMahon AD, Struthers AD, Connell JMC, McInnes GT, Ford I, MacDonald TM |
 |
Title(s) |
Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study |
|
Reference(s) |
BMC Cardiovasc Disord 2007;7:14 |
|
Disease |
Hypertension |
|
Purpose |
To test the hypothesis that the aldosterone:renin ratio predicts the antihypertensive response to spironolactone. Secondary, to determine whether bendroflumethiazide induces adverse metabolic abnormalities, especially in subjects with high aldosterone:renin ratios, and if baseline renin measurement predicts the antihypertensive response to spironolactone and/or bendroflumethiazide |
|
Study design |
Randomised, double-blind, crossover, controlled |
|
Follow-up |
Aim 26 weeks |
|
Patients |
Aim 120 patients with mild to moderate hypertension |
|
Treatment regimen |
Spironolactone, 50 mg once daily, or bendroflumethiazide, 2.5 mg once daily, for 12 weeks, followed by 2 weeks’ washout, then crossover for additional 12 weeks |
|
Results |
Not yet available |
|
|
|
